Literature DB >> 2571370

Use of scid mice to identify and quantitate lymphoid-restricted stem cells in long-term bone marrow cultures.

G M Fulop1, R A Phillips.   

Abstract

Mice homozygous for an autosomal recessive scid (severe combined immune deficiency) mutation on chromosome 16 exhibit a defect that specifically impairs lymphoid differentiation but not myelopoiesis. Consequently such mice are deficient in both humoral and cell-mediated immune functions. Despite their defect, scid mice survive under pathogen-free conditions and are fertile. The mutation does not impair the hematopoietic microenvironment necessary for lymphoid differentiation, since these mice can be cured with grafts of normal bone marrow (BM) or cells from long-term BM cultures (LTBMC); however, reconstitution requires sublethal (400 cGy) irradiation of recipients. Engraftment with cells from LTBMC gave near-normal levels of colony-forming B cells (CFU-B) in spleen and BM of the recipients by 6 weeks postgrafting. Since LTBMC are devoid of all mature B and pre-B cells but contain stem cells that restore lymphoid function in scid mice, we used a limiting-dilution assay to characterize and enumerate the number of stem cells in LTBMC capable of restoring lymphoid function. Curing was determined by the CFU-B-cell assay, since CFU-B are not detectable in normal scid mice. The results indicate that fewer cells from LTBMC than from fresh BM are required to obtain lymphoid reconstitution. As few as 10(3) LTBMC cells can repopulate significant B- and T-cell function in scid recipients. From these results we conclude that scid mice can be used as recipients to quantify lymphoid-restricted stem cells and that there is a functional separation of lymphoid- and myeloid-restricted stem cells in LTBMC with an enrichment for lymphoid-restricted stem cells in these cultures.

Entities:  

Mesh:

Year:  1989        PMID: 2571370

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Proliferation of totipotent hematopoietic stem cells in vitro with retention of long-term competitive in vivo reconstituting ability.

Authors:  C C Fraser; S J Szilvassy; C J Eaves; R K Humphries
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 2.  SCID mice in the study of human autoimmune diseases.

Authors:  M A Duchosal
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Uterine-derived stem cells reconstitute the bone marrow of irradiated mice.

Authors:  Zhuo Sun; Jun Wu; Shu-Hong Li; Yuemei Zhang; Munira Xaymardan; Xiao-Yan Wen; Richard D Weisel; Armand Keating; Ren-Ke Li
Journal:  Stem Cells Dev       Date:  2015-01-07       Impact factor: 3.272

4.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

Review 5.  Murine natural killer cell differentiation: past, present, and future.

Authors:  T A Moore; M Bennett; V Kumar
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Ectopic lymphokine gene expression in human peripheral blood lymphocytes in vivo.

Authors:  C A Chambers; J Kang; N Hozumi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-01       Impact factor: 11.205

7.  Developmental potential of the earliest precursor cells from the adult mouse thymus.

Authors:  L Wu; M Antica; G R Johnson; R Scollay; K Shortman
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

8.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

Authors:  I G Schmidt-Wolf; R S Negrin; H P Kiem; K G Blume; I L Weissman
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.